2.03% -0.1973

Lexeo Therapeutics Inc (LXEO)

Lexeo Therapeutics Inc (LXEO) 最新ニュース

Lexeo Therapeutics Inc (LXEO)

Lexeo Therapeutics Inc (LXEO) 最新ニュース

Objective long/short (LXEO) Report - Stock Traders Daily

Analysts Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Price Target at $22.14 - MarketBeat

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update - MarketBeat

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Buy” by Analysts - Defense World

Gene Therapies For Cardiomyopathies Market Growth Anticipated - openPR

The Globe and Mail - The Globe and Mail

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares - MarketBeat

Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences - StockTitan

Top investors say Lexeo Therapeutics Inc. (LXEO) ticks everything they need - SETE News

The Lexeo Therapeutics Inc. (LXEO) had a good session last reading, didn’t it? - US Post News

Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expands By 16.9% - MarketBeat

Trading (LXEO) With Integrated Risk Controls - Stock Traders Daily

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Average Price Target from Analysts - MarketBeat

Chardan Capital Comments on Lexeo Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:LXEO) - MarketBeat

Vanguard Group Inc. Grows Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat

Stifel maintains 'Buy' on Lexeo stock, confident amid trial progress By Investing.com - Investing.com Canada

Chardan Capital Weighs in on Lexeo Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:LXEO) - MarketBeat

Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Reaffirmed by Chardan Capital - Defense World

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expected to Earn Q3 2024 Earnings of ($0.64) Per Share - MarketBeat

Q3 2024 Earnings Estimate for Lexeo Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:LXEO) - Defense World

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expected to Earn Q3 2024 Earnings of ($0.64) Per Share - Defense World

Royal Bank of Canada Reiterates Outperform Rating for Lexeo Therapeutics (NASDAQ:LXEO) - Defense World

Lexeo Therapeutics (NASDAQ:LXEO) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat

Lexeo Therapeutics CEO sells $57.6k in company stock By Investing.com - Investing.com Australia

Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at Chardan Capital - MarketBeat

Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $21.00 at HC Wainwright - Defense World

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares of Stock - Defense World

Lexeo Therapeutics CEO sells $57.6k in company stock - Investing.com

Lexeo Therapeutics (NASDAQ:LXEO) Given New $21.00 Price Target at HC Wainwright - MarketBeat

Lexeo Therapeutics (NASDAQ:LXEO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat

Comparing Cognition Therapeutics (NASDAQ:CGTX) & Lexeo Therapeutics (NASDAQ:LXEO) - Defense World

LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024 - InvestorPlace

LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024 - MSN

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewswire

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - StockTitan

Lexeo Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily

American International Group Inc. Invests $79,000 in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World

Contrasting Lexeo Therapeutics (NASDAQ:LXEO) & Kiromic BioPharma (NASDAQ:KRBP) - Defense World

Janus Henderson Group PLC Acquires 210,047 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat

Robert W. Baird gives an Outperform recommendation for Lexeo Therapeutics Inc. (LXEO) - Knox Daily

BNP Paribas Financial Markets Takes Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

LXEO (Lexeo Therapeutics Inc.) may reap gains as insiders became active recently - Knox Daily

Lexeo Therapeutics Inc. (LXEO) deserves closer scrutiny - US Post News

Lexeo Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.59) Per Share, Leerink Partnrs Forecasts (NASDAQ:LXEO) - Defense World

Q3 2024 EPS Estimates for Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Decreased by Analyst - MarketBeat

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates - Yahoo Finance

Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data - Markets Insider

Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key CompaniesRetrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics - India Shorts

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further (NASDAQ:LXEO) - Seeking Alpha

Friedreich's Ataxia Market to Grow at a Substantial Growth - GlobeNewswire

Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key CompaniesRetrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics - Yahoo Finance

Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at HC Wainwright - MarketBeat

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data - Yahoo Finance

Lexeo Therapeutics’ (LXEO) “Buy” Rating Reaffirmed at Chardan Capital - Defense World

Lexeo Therapeutics’ (LXEO) “Buy” Rating Reaffirmed at Chardan Capital - American Banking and Market News

Ratios in Focus: Analyzing Lexeo Therapeutics Inc. (LXEO)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Insight venture partners executives sell over $61 million in nCino shares By Investing.com - Investing.com India

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet - MSN

LXEOに似た銘柄